Education

Universidad Peruana Cayetano Heredia, 2000

Internships

Emory University, 2003, Internal Medicine

Residency

Emory University, 2005, Internal Medicine

Fellowships

University Of California San Diego Med Ctr, 2008, Pulmonary Disease

Certifications

American Board of Internal Medicine-Critical Care Medicine
American Board of Internal Medicine-Internal Medicine
American Board of Internal Medicine-Pulmonary Disease

Publications

• C Kytasty, CY Lin, LM Alvarez, A Chan, MA Ferrada, PW Finn, TD Bigby. Interferon β Attenuates Airway Hyperresponsiveness and Allergic Inflammation in a Mouse Asthma Model. American Journal of Respiratory and Critical Care Medicine, 175:A504, 2007.
• Carbajal J, Melgarejo C, Leey J, Dulanto R, Sánchez-Sierra M, Kanamori M, Alvarez LM, Hernández K, Accinelli R. Acute Mountain Sickness among Peruvian Children. American Journal of Respiratory and Critical Care Medicine, 167:A925, 2003.    
• Accinelli R, Pro L, Reyes M, Salazar J, Chiarella P, Guio H, Alvarez LM. The creation of a pilot asthma program decreases pneumonia rates. American Journal of Respiratory and Critical Care Medicine, 165:A745, 2002.
• Accinelli RA, Alvarez LM, Valles PM, Guio H, Munoz P. Annual risk of tuberculosis infection among medical students of Universidad Peruana Cayetano Heredia in Lima-Peru. American Journal of Respiratory and Critical Care Medicine 165:A439, 2002
• Accinelli RA, Hernandez K, Alvarez LM, Pantoja C, Vidal L, Ibanez R, Hinojosa G, Robles L. Risk factors for failing, dying and defaulting among TB patients treated with DOTs. American Journal of Respiratory and Critical Care Medicine, 165:A439, 2002.
• Accinelli RA, Alvarez LM, Chirinos E, Amat O, Hernandez K. Effectiveness of DOTs for new tuberculosis cases in Peru. American Journal of Respiratory and Critical Care Medicine, 165:A291, 2002.
• Accinelli RA, Alvarez LM, Chirinos E, Amat O, Hernandez K. Effectiveness of the retreatment scheme 1 HRZES / 2 HRZE / 5 H2R2E2 for patients who have failed to DOTs. American Journal of Respiratory and Critical Care Medicine,  165:A291, 2002.
• Alvarez LM, Accinelli RA, Hernandez K, Diaz J, Salazar D, Gayoso O. Daily three months isoniazid prevents PPD conversion among preschool contacts of a known tuberculosis case in a hospital’s day care center in Lima, Peru. American Journal of Respiratory and Critical Care Medicine, 165:A291, 2002.
• Accinelli RA, Alvarez LM, Chirinos E, Amat O, Hernandez K, Portocarrero J. Treatment of failing tuberculosis cases to 1 HREZS / 2 HREZ / 5 H2R2E2 with            3 KCxEtZE / 15 CxEtZE in Peru. American Journal of Respiratory and Critical Care Medicine 165:A18, 2002.
• Accinelli RA, Alvarez LM, Diaz J, Yshii C, Aliaga A, Chavez W, Cornejo M, Chirinos E, Martinez H, Gayoso O. Tuberculosis among health-care workers of a general hospital in Lima, Peru. American Journal of Respiratory and Critical Care Medicine, 163:A965, 2001. 

Research

Peer-reviewed:

• Chan A, Balasubramanian M, Blackledge W, Mohammad OM, Alvarez L, Boss GR, Bigby TD. Cobinamide is superior to other treatments in a mouse model of cyanide poisoning. Clin Toxicol (Phila), 48:709-717, 2010. 
• KE Broderick, L Alvarez, M Balasubramanian, DD Belke, A Makino, A Chan, VL Woods Jr., WH Dillmann, VS Sharma, RB Pilz, TD Bigby and GR Boss. Nitrosyl-Cobinamide, a New and Direct Nitric Oxide–Releasing Drug Effective In Vivo. Experimental Biology and Medicine, 232:1432-1440, 2007.

Non-funded research:

• Impact of functional endoscopic sinus surgery on cystic fibrosis. Co-investigator with: Julie Biller MD, Diana Quintero MD, David Poetker MD and Todd Loehrl MD

Industry-sponsored research:

• Co-Investigator with Vertex Pharmaceuticals: A phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of VX-770 in subjects with cystic fibrosis and the G551D mutation. Principal investigator at Medical College of Wisconsin: Julie Biller MD
• Co-Investigator with Insmed: TR02112: a phase 3 randomized, double blind, placebo controlled study of liposomal amikacin for inhalation (Arikace) in patients with recalcitrant nontuberculous mycobacterial lung diseases. Principal investigator at University of Miami: Matthias Salathe MD
• Co-investigator with Abbvie, Janssen Pharmaceuticals, Aptalis Pharma,Iinc.: A long term prospective observational safety study of the incidence of and risk factors for fibrosing colonopathy in us patients with cystic fibrosis treated with pancreatic enzyme replacement therapy: A harmonized protocol across sponsors. Principal investigator at University of Miami: Matthias Salathe MD 
• Co-investigator with KaloBios Pharmaceuticals Inc: KB001A-05. A phase 2, randomized, double-blind, placebo-controlled, repeat-dose study of KB001-A in subjects with cystic fibrosis infected with Pseudomonas aeruginosa. Principal investigator at University of Miami: Matthias Salathe MD 
• Co-investigator with Gilead Sciences, Inc.: GS-US-205-0170. A phase 3, randomized, double-blind, placebo-controlled, multicenter study of aztreonam for inhalation solution (AZLI) in a continuous alternating therapy (CAT) regimen of inhaled antibiotics for the treatment of chronic pulmonary Pseudomonas aeruginosa infection in subjects with cystic fibrosis. Principal investigator at University of Miami: Matthias Salathe MD 
• Co-investigator with Savara Pharmaceuticals: SAV00502. A phase 2, randomized, double blind, placebo controlled study of Aerovanc for the treatment of persistent methicillin resistant Staphylococcus aureus lung infection in cystic fibrosis patients. Principal investigator at University of Miami: Matthias Salathe MD
• Co-investigator with Vertex Pharmaceuticals: A phase 3, randomized, double blind, placebo controlled, parallel group study to evaluate the efficacy and safety of lumacaftor monotherapy and in combination with ivacaftor in subjects aged 12 years and older with cysticfibrosis, homozygous for the F508del CFTR mutation. Principal investigator at University of Miami: Matthias Salathe MD 
• Co-investigator with Janssen Pharmaceuticals: JSPP1201. A point prevalence study to evaluate the prevalence of antibodies to selected porcine viruses in patients with cystic fibrosis who are receiving porcine derived pancreatic enzyme replacement therapy: A harmonized protocol across sponsors. Principal investigator at University of Miami: Matthias Salathe MD
• Co-investigator with Vertex Pharmaceuticals: A phase 2, multicenter, double-blinded, placebo-controlled, multiple-dose study to evaluate safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of lumacaftor monotherapy, and lumacaftor and ivacaftor combination therapy in subjects with cystic fibrosis, homozygous or heterozygous for the F508del CFTR mutation. Principal investigator at University of Miami: Matthias Salathe MD 
• Co-investigator with Vertex Pharmaceuticals: VX12809105: A phase 3, rollover study to evaluate the safety and efficacy of long term treatment with lumacaftor in combination with ivacaftor. Principal investigator at University of Miami: Matthias Salathe MD

Professional Organizations

• American Thoracic Society
• European Respiratory Society